Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Impel Neuropharma Announces FDA NDA Submission of INP104 for Migraine

americanpharmaceuticalreviewNovember 19, 2020

Tag: Impel Neuropharma , INP104 , Migraine

PharmaSources Customer Service